Kinases involved in endodermal cancer growth and survival pathways

Kinases involved in endodermal cancer growth and survival pathways encompass a broad class of enzymes that regulate intracellular signaling in malignancies arising from endoderm-derived organs, such as the lungs, stomach, and intestines (National Cancer Institute, 2023). These kinases, including Receptor Tyrosine Kinases (RTKs) like EGFR and MET, and intracellular kinases like PI3K and BRAF, are pivotal components of the MAPK and PI3K/AKT/mTOR pathways (Nature Reviews Cancer, 2021). In endodermal cancers, these proteins often undergo mutations or over-expression, driving autonomous cell growth and metabolic shifts that favor tumor survival (PubMed, PMC7352658). Therapeutic intervention typically involves small-molecule inhibitors or monoclonal antibodies that block ATP binding or ligand interaction, effectively halting downstream signaling (StatPearls, 2023). Despite the success of these targeted therapies, clinical management is frequently complicated by the evolution of resistance mechanisms, such as gatekeeper mutations or the activation of bypass signaling loops (Journal of Clinical Oncology, 2022). Furthermore, the heterogeneity of endodermal tumors often necessitates combination therapies to address multiple nodes within these complex survival networks (Cell, 2020).

Other names

Endodermal cancer kinasesEndoderm-derived tumor kinasesGastrointestinal and respiratory kinase targets

Inhibition of phosphorylation-mediated signaling cascades that drive oncogenic growth and survival.